Extrawell Pharmaceutical Holdings Limited (0858.HK)
HKD 0.05
(2.04%)
HKD 0.05
(2.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 170.4 Million HKD | -74.61% |
| 2022 | 671.28 Million HKD | 1.78% |
| 2021 | 659.53 Million HKD | 2.67% |
| 2020 | 642.35 Million HKD | 1.39% |
| 2019 | 633.53 Million HKD | 370.98% |
| 2018 | 134.51 Million HKD | -10.15% |
| 2017 | 149.7 Million HKD | 1.97% |
| 2016 | 146.81 Million HKD | 1.29% |
| 2015 | 144.95 Million HKD | 1.89% |
| 2014 | 142.26 Million HKD | -44.33% |
| 2013 | 255.54 Million HKD | 90.25% |
| 2012 | 134.32 Million HKD | 19.16% |
| 2011 | 112.72 Million HKD | 8.58% |
| 2010 | 103.81 Million HKD | -0.3% |
| 2009 | 104.12 Million HKD | -4.51% |
| 2008 | 109.04 Million HKD | 2.2% |
| 2007 | 106.69 Million HKD | 37.66% |
| 2006 | 77.5 Million HKD | 9.84% |
| 2005 | 70.55 Million HKD | -27.86% |
| 2004 | 97.81 Million HKD | -8.65% |
| 2003 | 107.07 Million HKD | -20.03% |
| 2002 | 133.88 Million HKD | 3.16% |
| 2001 | 129.78 Million HKD | 84.13% |
| 2000 | 70.48 Million HKD | 10.7% |
| 1999 | 63.67 Million HKD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 170.4 Million HKD | -74.61% |
| 2023 Q2 | 673.83 Million HKD | 0.0% |
| 2023 Q4 | 170.4 Million HKD | 0.0% |
| 2022 Q2 | 657.08 Million HKD | 0.0% |
| 2022 FY | 671.28 Million HKD | 1.78% |
| 2022 Q4 | 671.28 Million HKD | 0.0% |
| 2021 Q2 | 648.07 Million HKD | 0.0% |
| 2021 Q4 | 659.53 Million HKD | 0.0% |
| 2021 FY | 659.53 Million HKD | 2.67% |
| 2020 Q4 | 642.35 Million HKD | 0.0% |
| 2020 FY | 642.35 Million HKD | 1.39% |
| 2020 Q2 | 638.29 Million HKD | 0.0% |
| 2019 FY | 633.53 Million HKD | 370.98% |
| 2019 Q2 | 633.72 Million HKD | 0.0% |
| 2019 Q4 | 633.53 Million HKD | 0.0% |
| 2018 Q2 | 142.85 Million HKD | 0.0% |
| 2018 Q4 | 134.51 Million HKD | 0.0% |
| 2018 FY | 134.51 Million HKD | -10.15% |
| 2017 FY | 149.7 Million HKD | 1.97% |
| 2017 Q4 | 149.7 Million HKD | 0.0% |
| 2017 Q2 | 150.38 Million HKD | 0.0% |
| 2016 Q2 | 160.23 Million HKD | 0.0% |
| 2016 FY | 146.81 Million HKD | 1.29% |
| 2016 Q4 | 146.81 Million HKD | 0.0% |
| 2015 Q1 | 136.9 Million HKD | -3.77% |
| 2015 Q4 | 144.95 Million HKD | 0.0% |
| 2015 FY | 144.95 Million HKD | 1.89% |
| 2015 Q2 | 136.9 Million HKD | 0.0% |
| 2014 Q1 | 240 Million HKD | -6.08% |
| 2014 FY | 142.26 Million HKD | -44.33% |
| 2014 Q4 | 142.26 Million HKD | 0.0% |
| 2014 Q3 | 142.26 Million HKD | -40.72% |
| 2014 Q2 | 240 Million HKD | 0.0% |
| 2013 Q2 | 298.68 Million HKD | 0.0% |
| 2013 Q4 | 255.54 Million HKD | 58.18% |
| 2013 Q3 | 161.55 Million HKD | -45.91% |
| 2013 Q1 | 298.68 Million HKD | 122.36% |
| 2013 FY | 255.54 Million HKD | 90.25% |
| 2012 Q2 | 146.15 Million HKD | 0.0% |
| 2012 Q1 | 146.15 Million HKD | 29.65% |
| 2012 FY | 134.32 Million HKD | 19.16% |
| 2012 Q4 | 134.32 Million HKD | 0.0% |
| 2012 Q3 | 134.32 Million HKD | -8.09% |
| 2011 Q4 | 112.72 Million HKD | 0.0% |
| 2011 FY | 112.72 Million HKD | 8.58% |
| 2011 Q2 | 113.02 Million HKD | 0.0% |
| 2010 FY | 103.81 Million HKD | -0.3% |
| 2010 Q4 | 103.81 Million HKD | 0.0% |
| 2010 Q2 | 123.02 Million HKD | 0.0% |
| 2009 Q4 | 104.12 Million HKD | 0.0% |
| 2009 FY | 104.12 Million HKD | -4.51% |
| 2008 FY | 109.04 Million HKD | 2.2% |
| 2007 FY | 106.69 Million HKD | 37.66% |
| 2006 FY | 77.5 Million HKD | 9.84% |
| 2005 FY | 70.55 Million HKD | -27.86% |
| 2004 FY | 97.81 Million HKD | -8.65% |
| 2003 FY | 107.07 Million HKD | -20.03% |
| 2002 FY | 133.88 Million HKD | 3.16% |
| 2001 FY | 129.78 Million HKD | 84.13% |
| 2000 FY | 70.48 Million HKD | 10.7% |
| 1999 FY | 63.67 Million HKD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -19.767% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 97.648% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | 75.987% |
| Qianhai Health Holdings Limited | 94 Million HKD | -81.278% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 81.678% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 81.145% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | 74.39% |
| PuraPharm Corporation Limited | 689.65 Million HKD | 75.291% |
| SSY Group Limited | 4.49 Billion HKD | 96.208% |
| JBM (Healthcare) Limited | 366.75 Million HKD | 53.536% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 84.373% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.899% |